Catch up on coronavirus: the 60 best treatments in development: The 60 COVID-19 therapies in development, more than two dozen have therapies that have appeared or been made public in two weeks because GEN operates on its original abbreviation for COVID-19 list A treatments.
Anthony Fauci, director of the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), was expecting COVID-19 and thousands of people around the world, whose lives have been cut short by the SARS-CoV-2 epidemic when he expressed his hope at a Congressional panel last week that the first patients would be vaccinated in the development of the new coronavirus “in a few weeks.”
Fauci’s hope came true on Monday, after less than a week, on Monday, to be exact, when Modern and NIAID, which Fauci has led since 1984, have served as potential remedies for the company. The first patient in a clinical trial of the candidate vaccine mRNA-1273. For COVID-19.
A stable prefabricated form of the spike protein (s) was encoded at the Kaiser Permanente Institute of the Washington Health Research Institute in Seattle. Despite this welcome development, vaccines and other treatments that reach COVID-19 may take some time to reach desperately needed patients.
In a recent note to investors, H.C. Wainwright’s managing director, senior healthcare analyst Raghuram Selvaraju, PhD, estimated that the clinical development of the COVID-19 vaccine would take approximately 18-24 months to complete. Most of the candidates for therapy for COVID-19 listed were vaccines found only in the animal testing stages.
Another Morningstar Damian Conover analyst said he benefited from the COVID-19 outbreak based on his work to seek new treatments. The companies he cited include vaccines and / or biopharmaceutical giants with experience in infectious diseases, but whose share prices are below their value.
Cited companies include GlaxoSmithKline, Merck & Co, Pfizer, and Sanofi, as well as Gilead Sciences, which have made headlines around the world through the development of Remedivir.
Gilead’s remasivir is one of the five candidates for treatment with COVID-19, considered the most promising based on recent development and / or activity.
Other top-tier treatments include ABV’s Caletra® (also marketed as aluvacci; lopinavir / rutanvir), the modern messenger RNA (mRNA) vaccine candidate mRNA-1273, Regeneron / Sanofi called Kevzara® (sarilumab), an arthritis medication that is now being tested for a serious COVID-19 infection;. And more recently, favipiravir, marketed by Fujifilm as Avigan®.
Those companies, and dozens of other drug developers and research institutes, are behind 60 active drug development programs in North America, Europe, and China, as highlighted by GEN in this updated list. More than two dozen of these treatments have emerged or been made public in just two weeks when General briefly published his original A list in COVID-19 treatments.
How to Win Coronavirus: The Top 35 Treatments in Development. Each potential developer is listed alphabetically by its developers, followed by a brief update on the name or description of the treatment, the type of treatment, including its mechanism, and recent developments.
In your case, the status update includes links to recent news reports on Gen, as well as clinical trial pages created by US authorities through clinictrials.gov and links by Chinese authorities in the form of the Chinese Clinical Trials Registry.
According to the Chinese Registry, many Chinese authorities, hospitals, and companies continue to study the treatment under the auspices of their original developers or any developer. One of the most recent examples of this is the first affiliated hospital of Wenzhou Medical University.
Whose researchers have launched a couple of clinical trials in China as thalidomide, one that prevents lung injury caused by COVID-19 (NCT04273529) or Treatment is intended as adjuvant therapy.
After a study evaluating thalidomide plus low-dose hormone adjuvant therapy for patients with another COVID-19 (NCT04273581), the drug showed positive results in treating patients with severe H1.11. Other collaborations related to COVID-19 focus on the development of technologies or platforms for the development of future treatments.
Teams from the National School of Tropical Medicine at Baylor College of Medicine (BCM) and the Vaccine Development Center at Texas Children’s Hospital have clinically constructed the spike protein receptor binding domain (RBD) for SARS and RBD of protein as COVID.
They are being developed from -19. Because the peak proteins of coronoviruses bind to receptors found in the host’s lung tissue. The BCM stated that additional preclinical tests are underway to search for a recombinant protein-based vaccine in clinical trials to determine whether it is safe, sufficiently protective or cross-reactive.
The most recent platform examples are Cedara Therapeutics, whose platform is to develop antiviral Fc conjugates for the treatment and prevention of serious respiratory infections by attacking viruses directly instead of cells in the lungs. On March 9, two researchers from the US Center for Disease Control and Prevention.
Larisa Gubareva, MD, PhD, and Tina Mohan, PhD, published in Cold Spring Harbor Perspectives in Medicine through a document that identifies monoclonal antibodies (mAbs). ) Pointing to the neurominidase (NA) epitope.
They and other efforts are taking place in a deadly race against time: According to the Johns Hopkins University Center for Systems Science and Engineering (CSSE), March 18 is 9:53 p.m. ET I know. With 8,244 people in 53 countries. Of those who died worldwide, 39% or 3,241 were in China. CSSE also recorded 204,264 confirmed cases of COVID-19, of which 40% (81,102) were in China.
Treatment: Kaletra® (also marketed as alluvia; lopinavir / ratanavir) Type: HIV-1 protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and children older than 14 days.
Status: On March 9, AbbVie confirmed that it is collaborating with health agencies and institutions to determine antiviral activity, as well as the efficacy and safety of the colletra against COVID-19.
Agencies include the European Health Authority, the FDA, the Centers for Disease Control and Prevention, the NIH, and the Advanced Biomedical Research and Development Authority (BARDA).
On March 16, researchers at the University of Queensland in Australia said they expected to begin large-scale trials of Kaletra® and chloroquine marketed by Bayer and other companies (see below), after both drugs with patients with COIDID-19. It was successfully treated.
The Chinese National Health Commission authorized Kalletra to treat pneumonia caused by SARS-CoV-2, AbbVie said on January 27. AbbVie has donated RMB 10 million from Kaletra ($ 1.4 million) to the Chinese authorities as an experimental alternative to support this growing public health crisis.
The Henan Province Health Commission announced on January 31 that three cases of diagnosis of patients with new coronovirus infections, recovered after combining cletra, ritonavir and lopinavir, were confirmed.
As of that date, nucleic acid tests of more than 20 confirmed cases of new coronovirus-infected patients admitted to hospitals in Zhejiang province, according to Eskletis Pharma, turned negative after taking Kalra, which appeared to be their own. candidates. ASC09 is evaluating combination therapy and rituals (see below).
2. AIM ImmunoTech
Treatment: Ampligen® (rintatolimod)
Type: immune modulator indicated for severe chronic fatigue syndrome.
Status: AIM ImmunoTech said in a prospectus on March 10 that it has partnered with ChinaguBroad, a pairing and counseling service for cross-border deals involving China, such as prophylactic / early-onset therapy against COVID to facilitate the entry of ampligen into China.
A day earlier, the company said Japan’s National Institute of Infectious Diseases (NIID) would study Ampligen as a potential treatment for COVID-19, through a study conducted at NIID and the University of Tokyo.
Treatment: single dose, intranasal vaccine designed to provide systemic immunity.. Type: A vaccine based on Altimmune’s proprietary platform vaccine technology, which the company implemented in the development of NasoVAX, the company’s influenza vaccine candidate that showed positive Phase IIa results.
Status: Ultimune stated on February 28 that it completed the design and synthesis of the vaccine, and was directed to animal testing and manufacturing. Clinical trials of the vaccine can begin in early August. The company also said it was “actively discussing with various potential partners.”
4. Apeiron Biologics
Treatment: APN01 – Type: Recombinant human enzyme altered by angiotensin 2 (rhACE2) for the treatment of acute lung injury, acute respiratory distress syndrome, and pulmonary arterial hypertension.
Status: On February 26, Vienna-based APEIRON began a pilot trial started by a pilot researcher in China designed to evaluate APN01 as a treatment for patients with severe SARS-CoV-2 infection.
The randomized, unconfirmed trial will treat 24 patients for seven days to obtain preliminary safety data, along with the effect of rhACE2 on biological, physiological, and clinical outcomes.
Sugle-based Anglepharma is coordinating Chinese clinical trials with the support of Shanghai-based DMM Pharmaceutical CRM.
5. Ascletis Pharma
Treatment: GNOVO® (Danoprevir) plus Ronovair; ASC09 and Ratanveer; ASC09 and oseltamivir; Ratanavir and Osteltamivir.
Type: HIV protease inhibitor
Status: On March 10, Escalitis reported progress in the oral clinic and rutonovir in their clinical research, indicating that all 11 patients treated with combination therapy had positive results in a test conducted at Nanchant Ninth Hospital (NCT04291729)… discharge from the hospital after showing up. Escalations announced the discharge of the first three patients in the study on February 26.
On February 2, Escalates stated that it was actively assisting “relevant medical institutions and medical researchers” in clinical trials evaluating the combination of Escalates ASC09 and ritonavir of COVID-19, following a request made to the company.
He is doing On January 25, Escalates requested the National Administration of Medical Products and its Medicines Evaluation Center, incorporating the ritual and the combination of fixed doses ASC09 in the National Emergency Channel.
Tongji Hospital in China is testing a combination of ASC09 and tamiflu (oseltamivir), ritonavir and tamiflu (oseltimivir), and tamiflu in .gov (NCT04261270) clinical trials alone. Temiflu is distributed in the United States by Genent, a member of the Roche Group under license from Gilead Sciences.
Additionally, a trial potentially registered by The First Affiliated Hospital of Zazz University School of Medicine is evaluating the combination of ASC09 and ritonavir, and lopinavir and ritonavir (ChiCTR2000029603).
6. Bayer and many Chinese manufacturers
Treatment: chloroquine phosphate (marketed by Bayer as Recochin®) Type: chloroquine phosphate salts, a quinoline compound with antimalarial and anti-inflammatory properties. Bayer discovered resochin and introduced it into clinical practice in 1947 for the treatment of malaria.
Status: Chloroquine has shown “quite good efficacy,” according to Surya Yanarong, deputy director of the Ministry of Science and Technology’s China National Biotechnology Development Center (MOST), after the state-owned Xinhua clinic on February 17.
Testing in more than 10 hospitals in Beijing, as well as in Guangdong province in southern China and Hunan province in central China.
On March 16, researchers at the University of Queensland in Australia said they hoped to start large-scale trials of chloroquine, as well as Caletra® from ABV (see above), with both drugs successfully treating patients with COVID-19 after doing.
Chinese news outlet Shine reported on March 10 that Bayer donated approximately $ 1.5 million (approximately $ 1.7 million) in drugs to the Chinese Red Cross to support the prevention, diagnosis, treatment.
And cooperation of COVID-19 in China. He made In response to a call from the Yunnan Province Department of Commerce, Bayer’s factory in Kunming, China, raised 50,000 disposable surgical masks and 10,000 R95 medical masks to be donated to the Kunming Red Cross Society.
In a study published Feb. 4 in Cell Research, a team of Chinese researchers reported that chloroquine and remediosvir were “highly effective in controlling the 2019-nCoV in vitro infection.”
After the Chinese National Health Commission included chloroquine phosphate in its latest treatment guidelines for COVID-19 pneumonia, eight Chinese companies pushed for the manufacture and supply of the drug, the Shanghai Daily reported on February 20.
7. Beijing Staidson Biopharma and InflaRX
Types: anti-C5a monoclonal antibodies in the development of COVID-19, as well as saprative hydarengitis, ANCA-associated vasculitis and pyoderma gangaraenosoma.
Status: Chinese authorities approved clinical trials of IFX-1 as COVID-19 treatment in February. The company has not listed IFX-1 as a COVID-19 treatment, only according to a presentation at the SVB Lerink Global Health Conference, “Further development for unknown chronic inflammation and autoimmune diseases.” Held from February 25 to 27.
8. Beroni Group
Treatment: Treatment is not based.
Type: None modified
Status: The Baroni Group said it will partner with Tianjin University in China on March 9 to follow animal experiments for a nano-based COVID-19 treatment beginning this month, then clinical trials, which is expected in April.
Type: Novel oral small molecule oral T-cell costimulant
Status: BeyondSpring declared that March 11 was an EE. USA Provisional Patent application BPI-002 filed for methods of treating viral infections, including COVID-19, when administered alone or in combination with a vaccine.
According to the company, BPI-002 can potentially activate the adaptive immune system (including CD4 + helper T cells and CD8 + cytotoxic T cells) and directly attack virus-infected cells, such as RNA viruses such as COVID-19.
When combined with a vaccine that includes the COVID-19 vaccine, causes BeyondSpring, BPI-002 can serve as an adjuvant to provide better long-term humoral (B-cell dependent) protection against future viral infections.
Treatment: Galsadivir (BCX4430)
Type: RNA polymerase nucleoside inhibitor designed to inhibit the viral replication process
Status: Biocryst said it held an active dialogue with United States public health officials on March 5 about whether brokers could be helpful among possible approaches to the treatment and prevention of COVID-19.
Gallicidewire has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including coronaviruses and viral disease families, including filaovirus, togavirus, bonavirus, armavirus, paramyxovirus, and flavivirus.
National Institute of Allergy and Infectious Diseases (NIAID) and EE. USA A phase II trial (NCT03891420) under a contract with the Department of Health and Human Services (HHS) evaluates galadisavir for yellow fever.
11. BioNTech, Pfizer and Fosun Pharma
Type: Potential first-class mRNA vaccine designed to induce immunity and prevent COVID-19 infection
Status: On March 17, BioNTech and Pfizer said they would partner to develop BNT162, which BioNTech announced a day earlier in person from their COVID-19-focused accelerated development program “Project Lightspeed.” The first treatment to emerge.
The companies said they hope to start clinical trials for BNT162 in April, as part of a global clinical development program in Europe (starting with Germany), the United States and China. S. And it will take place in many places in Europe. BioNTech and Pfizer said the financial terms and details of development, manufacturing and potential commercialization will be finalized in the coming weeks.
BioNTech is also partnering with Fosun Pharma to jointly develop BNT162 in China, and Fosun agrees to invest $ 50 million in capital. For up to 1,580,777 ordinary shares in BioNotech, and pay up to $ 85 million to BioNotech in payment of additional advance payments and milestones. The companies will share future gross profits from vaccine sales in China.
Type: anti-necrosis drug whose glycopolymer structure consists of hemoglobin molecules and hybrid molecules that integrate a proprietary polymer chemical structure. BXT-25 is the company’s flagship product candidate, which is designed to transport oxygen to tissues when blood flow is blocked.
Status: Boston-based Bioxytran said on February 5 that it was one of the “international pharmaceutical companies” to develop BXT-25 as a treatment for acute respiratory distress syndrome (ARDS) in end-stage patients with SARX- CoV-2. It is partnering with. Since BXT-25 is 5,000 times smaller than red blood cells, the company will use MDX Life Sciences’ MDX Viewer to assess the drug’s safety and efficacy.
13. CanSino Biologics
Treatment: COVID-19 prevention vaccine
Type: new recombinant coronavirus disease vaccine involving adenovirus type 5 vector (Ad5-nCoV)
Status: Cancino said on March 18, approval was received from the Chinese authorities to begin human trials of the vaccine, developed jointly with the Beijing Institute of Biotechnology of China, the Academy of Military Medical Sciences and volunteers for the phase six months. I was looking according to reports from the Chinese media.
According to Cancino, the first novel coronavirus vaccine for COVID-19 is the candidate vaccine to advance to Phase I in China. The company also cited the results of preclinical animal studies, which reported that the vaccine candidate could induce strong immune responses in animal models.
Treatment: Peptides of the Ligand Antigen Epitope Presentation System (LAAPS) Type: Immunotherapy based on the patented CEL-SCI LiPS peptide platform technique targeting antigens within the NP protein of COVID-19 that antagonizes cytolytic T cell responses.
Such reactions attack virus-infected cell “factories” within the infected host to help eliminate the source of the virus and reduce infection, causing CEL-SCI. LEAPS peptides use conserved regions of the coronavirus to stimulate protective cell-mediated T-cell responses and reduce viral load.
Status: CEL-SCI stated that on March 9 it will develop an immunotherapy to treat COVID-19 and other diseases, for which pathogenic antigenic (S) peptide sequences have already been identified, including many other infectious diseases Select certain types of cancer, allergic asthma and allergies, CNS diseases like Alzheimer’s and autoimmune diseases like rheumatoid arthritis.
According to CEL-SCI, LAAPS has demonstrated the ability to design antigen-specific immunotherapeutic peptides in many animal models that preferentially target the immune response to the cellular, humer (antibody), or mixed response and to the critical T regulator.
They are able to increase. Treg) reactions. CEL-SCI received a $ 1.5 million grant from the NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases to conduct LEAPS-based arthritis treatment studies through IND.
15. Celularity and Therapeutics of Sorrento
Type: allogeneic cell therapy, ready to use, derived from natural placenta (NK) Status: In a company filing on February 27, Cellularity stated that its anti-COVID-19 build was generated in a few weeks, and that its DAR-T and DAR-NK cells soon became anti-COVID-19.
It will be manufactured for testing. “The companies began a clinical and manufacturing collaboration on January 30, designed to expand the therapeutic use of CYNK-001 cellularity to COVID-19. Sorrento and CYNK-001 cellularity evaluated the coronavirus, specifically agreed as a new therapy. potential for SARS-CoV-2.
Sorrento, which owns 25% of Cellularity, agrees to use the existing capacity at its cGMP cell therapy manufacturing facility in San Diego to complement Cellularity’s new CGMP facility in Floram Park, NJ. Sorrento said he is already in contact with “leading” scientists and local Chinese experts, who discuss the clinical and logistical validation requirements for monitoring CYNK-001 in China.
16. Chugai Pharmaceutical
Zhejiang Hisun Pharmaceutical. Treatment: tocilizumab and fevivirivir; tocilizumab.. Type: interleukin-6 humanized mAb target.. Status: On March 16, Peking University First Hospital evaluated more than 150 studies of patients marketed in China by Chugai Pharmaceutical in combination with Zhejiang Hissan Pharmaceutical-narcotic Favipirir in adults with COVID-19 (ChiCTR2000030894).
Including tikilizumab Fue Registered The 94-patient trial evaluating tocizulamab has only been registered with the Chinese authorities by the first affiliated hospital of the Chinese authorities (Anhui Provincial Hospital of China) (Chintarticular Hospital) (ChiCTR2000029765).
Roshey’s subsidiary Chugai said that on February 7, it donated 1 million (about $ 143,000) to the Red Cross in China to support efforts to control outbreaks of coronovirus in China.
17. Cocrystal and Kansas State University Research Foundation
Treatment: broad-spectrum antiviral compound
Type: Protect Barriers… Status: On March 6, Coconut said it was “aggressive” to develop new antiviral compounds to treat coronovirus infections, using its proprietary drug discovery platform.
The company is taking advantage of patent rights and antiviral compounds, licensed by the Kansas State University Research Foundation (“KSURF”), to treat coronovirus and norovirus, announced a deal on February 24.
Crystal said its main objective was to advance its pre-clinical development program and advancing collaboration as the program progresses through the clinical stages.
18. CSL and University of Queensland (UQ)
Type: Vaccine based on MF59®, a subsidiary technology owned by Securus, a subsidiary of CSL… Status: On February 12, CSL stated that it would provide technical expertise and a donation of MF59 to the University of Queensland Preclinical Development Program. CSL said the university would use the adjuvant to evaluate the viral proteins developed with its molecular binding technology.
The company also donated RMB 1 million ($ 143,000) to the Chinese Red Cross for efforts to combat the epidemic.
After nine days, the university announced that it had obtained evidence of a concept showing the feasibility of using a molecular clamping technology for a vaccine candidate, that the immune system could more easily identify, triggering a protective immune response.
Keith Chappell, PhD, reported that the Australian team experimented with 250 different formulations before settling on the candidate vaccine virus. UQ plans to produce larger quantities of the vaccine to allow for additional testing, then move on to investigative diagnostic testing after the middle of the year.
Type: mRNA-based coronavirus treatment based on the company’s vaccine platform. Status: On March 17, CureVac told reporters in a conference call that it had pledged to introduce animal trials of its mRNA-based vaccine COVID-19 in April and human clinical trials in the summer.
The update comes a day after the European Commission offered € 80 million ($ 88 million) to increase vaccine development and manufacturing. The Alliance for Epidemiological Preparedness Innovations (CEPI) awarded the company up to $ 8.3 million in January for accelerated vaccine development, manufacturing, and clinical trials.
During the briefing and in a statement two days ago, CureVac denied a report in the German newspaper Welt am Sonntag that the administration of President Donald Trump has raised funds to produce its vaccine specifically for the US market in the US. USA The Germany-based CureVac sought to be courted.
Then-CEO Dan Menchella visited the White House on March 2, along with other biopharmaceutical officials, while the German government pressured the company to stay tuned and produce its vaccines for Germany and Europe.
The U.S. Ambassador to Germany Richard Grenell denied the report via Twitter, but an anonymous spokesman for the German Health Ministry confirmed Germany’s interest in Curevac developing vaccines in a Reuters statement.
Menichella resigned on March 11 and was succeeded by former CEO and founder Ingmar Hoar, who took a temporary leave just five days later for medical reasons, “not due to a coronovirus,” the company said.
Treatment: Leronilamb (Pro 140)
Type: humanized IgG4 monoclonal antibody. Leronlimab is the prime candidate for CytoDyn, and a potential CCR5 antagonist for many therapeutic indications.
Status: On March 16, CytoDyn presented a revised IND and protocol for its phase II clinical trial evaluating leronimlab (PRO 140) in patients who experienced respiratory complications as a result of contracting COVID-19.
The trial is designed to evaluate 75 patients at 10 centers in the US. USA Enrolled patients are likely to have a treatment window for approximately 6 weeks. The company also corrected a press release from March 12 to reveal that the first patient had lost carboplatin treatment and that carboplatin and leronilam treatment would continue.
CytoDyn and Longen China Group said they would begin discovering leronlimab as a possible treatment for coronavirus and cancer on February 12.
According to Cyradine, leronimlab has successfully completed nine clinical trials in more than 800 people, including the completion of its primary endpoints in a pivotal Phase III trial in combination with standard antiretroviral therapy in HIV-infected treatment-experienced patients.
CytoDyn stated that it plans to file a BL with the FDA on HIV during the first quarter of 2020. Leronlimab has the FDA fast-track designation as a combination of therapy with highly active antiretroviral therapy (HAART) for HIV-infected patients and for triple negative metastatic breast. Cancer
21. Bio distributed
Treatment: bioengineers to fight the COVID-19 antibody
Type: Broadly neutralizing antibodies based on the company’s superhuman platform, which the company says is the world’s most advanced computationally optimized human antibody library for antibody discovery.
Status: Founding Partner, CEO, President and President of Distributed Bio, Jacob Glanville, PhD, told the South Korean newspaper Mellie Business that the company was able to extract five specific SARS-CoV-2 antibodies and convert them into different variants. Working for any antibody binds to the virus that causes COVID-19.
If a possible antibody is identified in April, it could be mass-produced from August or September, said Glanville, who launched the Netflix dinner series “Pandemic: How to Prevent an Outbreak” in January. He gained fame after being portrayed.
22. Eli Lilly and Abkalera
Treatment: to treat antibodies and prevent COVID-19
Type: Anti-SAR-VOC-2 antibody based on Abrelera’s epidemic rapid response platform.
Status: Eli Lilly and Abkalera said on March 13 that they partnered to jointly develop more than 500 unique fully human antibody sequences identified in a blood sample from one of the first US patients. USA In recovering from COVID-19 it will…
AbCellera will draw on the experience of the NIH National Institute of Allergy and Infectious Diseases (NIAID), the Dell and Betty Bumper Vaccine Research Center, to identify antibodies that bind to the pandemic strain of SARS-CoV-2.
Abelera and Lily agreed to share the initial development costs for a treatment equally, after which Lily agreed to oversee all additional development, manufacturing and distribution. If successful, Lily will work with global regulators to provide treatment for patients.
23. Emerging biosolution
Treatment: COVID-HIG and COVID-EIG
Type: Human polyclonal hyperimmune for SARS-CoV-2 (COVID-HIG) for patients with severe hospitalization and protection for individuals at risk; Polyclonal hyperimmune derived with antibodies against SARS-CoV-2 (COVID-EIG) for seriously hospitalized patients.
Status: Emerging Biosolution said on March 11.
It started developing COVID-HIG and COVID-EIG using its Hyperinmune platform. Hyperimmuns are plasma-derived polyclonal antibody therapies that take advantage of immune responses in humans or animals and can provide immediate protection against infection.
Emergent said he launched plasma collection efforts for human and equine platforms in the third quarter, with the goal of building clinical materials within the next four to five months before beginning a clinical study.
24. Enanta Pharmaceuticals
Treatment: to prescribe
Types: existing antiviral and respiratory candidates, and drugs to be discovered. Status: Enanta said on March 13 that it had started a program to search for candidates for direct-acting antiviral drugs for the treatment of COVID-19, using a dual approach: for potential activity against the virus.
Candidates who use their experience in direct acting antiviral mechanisms test compounds from their library of antiviral compounds and discover new ones. Four days later, Baird Equity Research cited that strategy and the company’s antiviral experience to improve Enanta to “superior performance”: “In our view, NIAT’s core competencies are tackling the COID-19 epidemic. It’s an adjustment perfect “.
Enenta also stated that it will initiate Phase II dosing studies in patients with pediatric respiratory syncytial virus (RSV) and a Phase II study in adult transplant patients with RSV, in addition to phase IIb RSVP in adult patients with community-acquired RSV. Study included.
Since high-risk older adult patients such as RSV and those with a weakened immune system appear to have a similar patient profile to that of COVID-19 patients.
25. Fujifilm Holdings and Zhejiang Hisun Pharmaceutical
Treatment: fevipirvir (as avigan for fujifilm and as fevilvir for hyssun in China)… Type: broad-spectrum antiviral agents that selectively and potentially inhibit the RNA-dependent RNA polymerase (RDRP) of RNA viruses. Japan has approved Avigan for new or reemerging influenza and was previously used to treat Ebola patients in Guinea.
Status: Zhang Shinmin, an official with the Chinese Ministry of Science and Technology, told reporters on March 17 that favipirvir produced positive results in clinical trials in Wuhan and Shenzhen, including 340 patients, including a shorter time after treatment.
It includes patients who tested negative for COVID-19 for 11 to 4 days, and 91% of untreated patients received lung function. Improving the situation, as 62% of untreated patients, is measured by X-ray.
Japan’s Health Minister Katsanobu Kato said on February 22 that his ministry would recommend Avigen developed by Fujifilm-owned Toyama Chemical for use as a post-test treatment for the coronovirus in at least two medical institutions.
It appeared effective in mild and asymptomatic cases. In China, on February 17, the National Health Commission approved Hissun’s version as an investigational treatment for SARS-CoV-2 in an upcoming clinical trial to be held in Shenzhen.
26. Genrex Biotechnology
Treatment: eye peptide vaccine
Type: Vaccine based on Genrex’s I-Key immune system activation technology platform. Status: On March 4, Genreux stated that he would use the Epivapus computational tool, which can be used to estimate Epsops, a peptide vaccine against SARS-CoV-2 using the Li-Key technique. It can be used to generate. The companies were linked after Epivix identified several amino acid sequence hot spots of the SARS-CoV-2 protein.
Using Epivax’s predicted episodes, Genrex agreed to create a series of synthetic amino acid peptides that mimic the virus epitope and send them to the Chinse researchers for analysis on blood samples from those patients. They are those recovered from COVID-19. The research team plans to select the best I-Key hybrid peptides to produce a commercially viable vaccine, Genreux said.
On January 27, Zenrex said it had received a contract from the China Technology Exchange, Beijing Zhonghua Investment Fund Management Company Limited, Institute of Biology of the Shandong Academy of Sciences, and Sinotech-Advocates International Industry Development (Shenzhen) Company Limited.
Comment from Ii-Key. Generex said it would receive $ 1 million to start project work in the US. US, $ 5 million in license fees for the Ii-Key technology, payments from the Chinese consortium for all costs and expenses related to the development of the COVID-19 vaccine AND a 20% royalty for each dose of vaccine produced.
27. Gilead Sciences
Treatment: Remedisvir (GS-5734)
Type: nucleotide prodrug.. Status: Richard Adams Richard Children, assistant surgeon general and lung specialist at NIH, told The Wall Street Journal in a report published March 13 that Remedsvir showed a positive impact on the 14 Americans with SARS-CoV-2 in Diamond Princess He was hired a cruise ship, and received medications during treatment in Japanese hospitals.
The NIH announced on February 25 that it would be the first American clinical trial to evaluate experimental treatment for COVID-19 by evaluating remedisavir in patients at the University of Nebraska Medical Center in Omaha, where some Americans with the disease are being cared for. . Going or quarantining Remdesivir showed “no adverse events” when confirmed to be infected with SARS-CoV-2. Reported in a case study.
Clinical trials of Remedisvir from Gilead Sciences have started in China after being approved by the China-Japan Friendship Hospital and the Chinese Academy of Medical Sciences by the National Administration of Medical Products in China. Remedisvir and chloroquine phosphate were “highly effective in controlling the 2019-nCoV in vitro infection,” a team of Chinese researchers reported in a study published Feb. 4 in Cell
28. GlaxoSmithKline and Clover Biopharmaceuticals
Treatment: COVID-19S trimmer
Type: protein-based coronavirus vaccine
Status: GSK agreed to provide Clover with its Epidemic Assistance System for further evaluation of the S-trimmer in a preclinical study, the companies said on February 24 as part of a research collaboration.
The value of which was not disclosed. GSK reasons that Clover can quickly scale up and produce a new coronovirus vaccine in large quantities because it has one of the highest commercial scale cGMP biofeedback capabilities in China.
GSK is the world leader in vaccines, and partnering with them raises our expectations of both time-bound vaccine development and the ability to produce it in the large quantities necessary to prevent outbreaks of coronovirus, Michael Breen, Director of Infectious Diseases at GlobalData, Pharma.
29. iBio and Beijing CC-Pharming
Treatment: vaccine to prevent SARS-CoV-2 infection
Type: Plant-derived vaccines SARS-CoV-2 virus-like particles (“VLP”) – Constructed using Ibio’s Fastparming System ™, designed to produce nanoparticles and purify them, plants.
Status: On March 18, iBio made progress toward developing vaccine candidates, including the creation of constructs and four interim US support VLP platforms and other technologies to treat or prevent SARS-CoV-2 infections. Patent applications were reportedly filed on March 11.
On February 3, iBio and Beijing CC-Pharming unveiled plans to develop and test the COVID-19 vaccine, combining the vaccine’s R&D experience, including CC-Pharming and CSO President Kevin Wang, PhD, and Work in MERS-coronavirus, from iBio. VP Upstream Bioprocessing Sylvain Marcel, PhD, in Rapid Design of Manufacturing Processes for Biopharmaceutical Production in Plant-Based Expression Systems.
If this was successful, the research will distribute candidates for production at iBio’s Fastparming manufacturing facility, built in 2010 with funding from the Defense Advanced Research Projects Agency (DARPA). The facility is equipped with automated vertical growing and hydroponic systems designed to produce biology, using a relative of a tobacco plant.
30. Immunoprecess antibodies
Treatment: vaccines and neutralizing antibodies to coronoviruses. Type: Prophylactic and therapeutic compounds using ImmunoPrecise’s proprietary discovery platforms (including B Cell Select ™ and Dipedisplay ™) up to OmniAb®, a transgenic animal platform for direct generation of human antibodies.
Status: On March 12, ImmunoPrecise announced its approach to develop the COTID-19 treatment, called PolyTope mAb Therapy ™, a defined antibody combination designed to attack multiple epitopes and viral evasion mechanisms. Has been made. PolyTope mAb Therapy implements the company’s discovery platform and artificial intelligence capabilities through its partner partner EVQLV.
On February 20, ImmunoPrecise stated that it had appointed Il Roodink, PhD, as Global Leader of the Coronavirus Project, as chair of the Todem Scientific Committee.
31. Incyte, Shanghai Hengrei Pharmaceutical
Treatment: cambrizumab and thiamocin
Type: manned monoclonal antibody directed to PD-1 (Camrelizumab); The 5-da polypeptide hormone is secreted by the thymus gland (thymosin).
Status: Chinese clinical trials evaluating combination therapies have been registered by Wuhan Jininton Hospital (Wuhan Infectious Disease Hospital) (ChiCTR2000029806) and Southeast University (NCT04268537).
32. Biomedical impact
Treatment: linebacker and equivalency
Type: Angiotensin 2-converting enzyme (ACE2) and unspecified compounds with the ability to bind to the entry of SARS-CoV-2 into cells.
Status: Impact Singapore’s parent company eDevelopment said on March 18 that Research and Impact Research partner GRDG Sciences conducted a molecular coupling study using advanced computational models, demonstrating that its Linebacker and Equivir compounds were successfully delivered by SARS-CoV -2 Infection is prevented.
The compounds were shown to block 3 integral viral mechanisms for replication and infection by SARS-CoV-2: points of interaction of viral peaks, helicases, and proteases.
33. Pharmaceutical innovations
Type: Defensin mimicry in stage II development of oral musculature in patients with head and neck cancer
Status: The innovator said March 10 that trials of Brilacidin as a possible COVID-19 treatment would begin the week of March 16 in an undisclosed US regional biocannulation laboratory.
The company stated that Brilacidin was a compelling candidate due to its unique properties to mimic the human innate immune system and a mechanism of action, including disruption of pathogen membranes, which can lead to cell death.
On February 24, Innovation said it entered a material transfer agreement with an undisclosed “leading virology laboratory in the United States” to study Brilacidin for SARS-CoV-2. If the laboratory tests are successful.
Abhinav said, it will accelerate Brilacidin’s research and clinical development “through pharmaceutical associations, educational collaborations and government grants.” The innovation has also submitted a preliminary summary of Brilacidine for coronavirus treatment to the Advanced Biomedical Research and Development Authority (BARDA).
34. Innovio Pharmaceuticals and Beijing Advaskin Biotechnology
Type: DNA vaccine
Status: Innovio said on March 12 that he had received a $ 5 million grant from the Bill & Melinda Gates Foundation to increase testing and expansion of the CELLECTRA® 3PSP for intradermal delivery of the INO-4800. It is a smart device that works with A..Battery.
Innovio is partnering with Beijing Advaskin Biotechnology in a Phase I trial in China to develop INO-4800 as a treatment for coronavirus. Parallel to the company’s clinical development efforts.
Innovio said Advokane Biotechnology’s expertise will be leveraged in Beijing on January 30 to support the company’s clinical development efforts in the United States, as well as to develop INO-4800 as a coronavirus treatment.
Innovio has stated that he will develop the INO-4800 through Phase I testing in the United States, and has begun preclinical testing for the manufacture of clinical products. The ENO-4800 development is also supported by a $ 9 million grant from the Alliance for Epidemiological Preparedness Innovations (CEPO).
35. Janssen Pharmaceutical Cos.
(Johnson and Johnson)
Treatment: Prezcobix ™ (darunavir and caboobistat); Vaccine to develop with BARDA
Type: HIV protease inhibitors (Prescobix); Type of vaccine to develop..
Status: Janssen said that on January 29, he donated 300 boxes of prezcobics to the Shanghai Public Health Clinical Center and Wuhan University Jhonjon Hospital for use in research to support efforts to find a solution against SARS-VOC- two .
The Chinese Control Center for Laboratory Research and a further 50 containment boxes have been provided. Prezcobix is being studied in a trial sponsored by the Shanghai Clinical Center for Public Health (NCT04252274), while a Chinese trial combined with Prezcobix or the combination of lopinavir-ritonavir thymosin a1 (ChiCTR2000029541).
Separately, Janssen stated that on February 11, it expanded the existing collaboration with the Advanced Biomedical Research and Development Authority (BARDA) to develop a candidate vaccine for SARS-CoV-2.
The partners agreed to share research and development costs and experience to help Janssen’s COVID-19 research vaccine accelerate clinical trials. Janssen said he is working closely with global partners to accelerate the discovery of potential COVID-19 therapies to detect his library of antiviral molecules.
36. Janssen Pharmaceutical Cos. (Johnson & Johnson) + Beth Israel Deaconess Medical Center (BIDMC)
Treatment: preventive vaccine for COVID-19
Type: Vaccine based on Janssen’s AdVac® and PER.C6® technologies. Janssen noted that the research and preclinical collaboration were conducted with BIDMC’s Virology and Vaccine Research Center to develop vaccines for GICA and HIV.
Status: Janssen Pharmaceuticals said March 13 that he and Beth Israel DeConcé began preclinical testing of “multiple” vaccine possibilities, with the goal of identifying a COVID-19 vaccine candidate for clinical trials by the end of March.
Janssen has expressed optimism that he could launch a Phase I clinical study of a potential vaccine candidate before the end of the year “in collaboration with several global strategic partners.
Janssen said he is preparing to increase the level of production and manufacturing capacity to meet the needs of global public health vaccination.
37. Johns Hopkins
Treatment: antibodies against SARS-CoV-2
Type: Antibodies against blood plasma or serum from people recovering from COVID-19 infection.
Status: Johns Hopkins researchers Arturo Casadevall, MD, PhD, and Liise-anne Pirofski, MD, published an article in the Journal of Clinical Investigation on March 13 detailing their treatment approach for COVID-19.
Human Summoning It is an option for the prevention and treatment of COVID-19 disease serum that may become increasingly available when there are a sufficient number of people who have recovered and donate serum containing immunoglobulin. They are spun.
The Johns Hopkins research team has invested seed money into the Cassadeval project to purchase the equipment and establish an operation in Baltimore. According to Johns Hopkins, Casadeval and his team are now working with state and federal authorities to try to secure more resources.
Treatment: anti-corona immunoglobulin (IgG)
Type: Company-owned plasma-derived IgG platform technology polyclonal immunoglobulin as a potential treatment for critically ill patients with coronovirus.
The treatment is expected to originate from plasma derived from donors recovered from the virus, which is estimated to contain antibodies against COVID-19.
Status: Kamada announced plans for the development of an anti-crown IgG on March 11, stressing that its development and manufacturing plans depended “largely” on the availability of hyperimmune plasma and the prescribed regulatory pathway of treatment.
We are working with the Israeli regulatory authorities and local medical institutions to advance our program, said Kamda CEO Amir London.
(Applied DNA Sciences) and Takis Biotech
Treatment: linear DNA vaccine
Type: based on linear DNA produced by PCR designed to induce antibodies that can neutralize SARS-COV-2. Four preclinical vaccines based on the structure of the “spike” proteins have been prepared, which allow them to transcend the coronovirus by binding to specific receptors on the host cells.
Status: Applied DNA Sciences said on March 4 that four DNA vaccine candidates for preclinical testing on animals would be produced this month through the company’s proprietary PCR-based (“linear”) DNA manufacturing systems.
James A. Hayward, President and CEO, stated that within a few weeks of arrival we hope to quickly scale up the PCR-based production of each vaccine candidate and send them back to talkies, which will determine the relative capabilities of each vaccine in the vaccine . Applied DNA and LineaRx.
LineaRx, a wholly-owned subsidiary of Applied, and Rome-based Takis Biotech said on February 7 they formed a joint venture to develop preclinical vaccines using PCR-based DNA manufacturing technology.
The companies said that the benefits of their technology include the speed of production, the absence of antibiotics and their resistance genes, the purity of DNA, the simplicity of the design, the powerful immunogenicity proven in a pre-linear DNA vaccine, the absence of bacterial contaminants and the effectiveness of vaccine genes without insertion into the patient’s genome.
Treatment: INOmax® (nitric oxide)
Type: inhaled nitric oxide (iNO) indicated in periodical and short-term Americans and newborns with hypoxic respiratory failure associated with pulmonary hypertension.
Status: On March 12, Mallinckrodt said it was evaluating “limited published evidence” of a potential role for its marketed INOmax as a complementary measure in the treatment of patients with SARS-CoV-2 and associated lung complications.
The company cited an in vitro study showing the inhibitory effect of iNO on the replication cycle of severe acute coronavirus related to acute respiratory syndrome (SARS-CoV) in 2005, and a 2004 study showing better blood oxygen, low supplemental oxygen level and six SARSs The ventilator support was shown to be lower. -VOV patients are treated with iNO.
Mallinckrodt said he had informed the NIH about the assessment of acute respiratory distress syndrome (ARDS), informed the Advanced Biomedical Research and Development Authority (BARDA) of his ongoing study, and sent it to East India. The initial discussion began. with the FDA. Package supporting the possible use of iNO in ARDS associated with coronavirus.
Treatment: vaccine candidate and antibody
Type: Vaccine antibodies and virus-like particle (VLP) antibodies, SARS-CoV-2, developed through the company’s plant-based technology platform led by the Infectious Disease Research Center at Laval University Gary Kobinger, Ph.D. Hua, whose laboratory developed a successful Ebola vaccine.
That research is being partially funded by the Canadian Institute for Health Research. Status: Medicogo stated that on March 12, 20 days after acquiring the SARS-CoV-2 gene, it successfully produced the VLP coronovirus, the first step in developing a vaccine for COVID-19. The vaccine is expected to undergo preclinical testing for safety and efficacy, followed by summer (July / August) by 2020.
Treatment: RYONCIL ™ (Remestamcell-L)
Type: Candidate allogeneic mesenchymal stem cell (MSC) product for the treatment of host disease (AGVHD) versus pediatric acute steroid refractory grafts now under LDA review. A BLA was introduced in January.
Status: Mesoblast said March 10 is in active discussion with the government and regulatory authorities, medical institutions and biopharmaceutical companies to evaluate remestasel-L in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19. This is your plan to do.
The company cited a clinical study published in February that reported that functional MSCs were cured or significantly improved in the seven patients treated for severe COVID-19 pneumonia. Mesoblast also cited a post-hoc analysis of a study for presentation at a future conference of patients with chronic obstructive pulmonary disease (COPD).
Which reduces inflammation-reducing biomarkers and increases inflammatory biomarkers. Significantly improves lung functions in patients. The same inflammatory biomarker is also elevated in COVID-19.
Silobio Itesu, a mesoblast physician, told the general: “As a result, remastemcel-L may be an effective treatment to reduce high mortality in COVID-19 patients who are aging, increase the biomarker of inflammation and moderate they are serious.” “Clinical trials with remestamcell-L in ARDS associated with COVID-19 disease are expected to start soon.”
Type: New mRNA vaccine encapsulated in lipid nanoparticles (LNP) that encodes a stable prefabricated form of the spike protein (S).
Status: According to reports, on March 16, Modern was scheduled to dose the first patient in the first stage, a mRNA-1273 dose test trial (NCT04283461) to be conducted at the Kaiser Permanente Washington Health Research Institute in Siena.
The study will evaluate the safety and reactivity of the vaccination program of 2 doses of mRNA-1273 in healthy adults at 3 doses, 28 days apart. The first batch of MRNA-1273 was shipped to the NIH National Institute of Allergy and Infectious Diseases (VIR) Vaccine Research Center (VRC) in February, in association with Modern in vaccine design.
Treatment: antiviral therapy based on the company’s new nanomedicine platform. Type: Broad-spectrum virus binding ligand: “It’s like ‘Venus-fly-trap’ for viruses”, Anil R. Says Dewan, PhD, President and CEO.
Status: NanoViricides confirmed on January 30 that it was developing a COVID-19 treatment, claiming that “it had already found some key candidate ligands in its chemical library” that bind to peak SARS-CoV proteins. It can bind only to the cognitive receptor. angiotensin enzyme type 2 (ACE2).
Nanoviricide technology is based on mimicking the receptor on the human cell surface to which the virus binds, and forms lindands that chemically bind to a nanoelectric, forming a nanowaricide®.
When a virus is exposed to a nanoviricide, the nanoelectric polymer is designed to fuse with the lipid envelope of the virus. The company said it has begun preparing tests for potential candidates in cell cultures against “low threat” using the ACE2 receptor in its BSL-2 virology laboratory at its “Shelton, CT” campus.
NanoViricides said it is working on developing collaborations to advance its COVID-19 program in the event that an effective drug candidate is identified. If the preparatory work suggests the ability to develop a successful antiviral, Nanovirides said in a quarterly report on Form 10-Q filed on February 24.
It would seek a license from the licensees of its technology, Deracor allows the use of coronaviruses, which 90% owned by Anil Dewan, President and President of NanoViroCides, PhD.
45. Novavax + Emerging Biosolution
Treatment: vaccine candidate to be selected
Type: Vaccines designed to implement the company’s proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus peak proteins.
Novavax said it hopes to use it with its proprietary saponin-based Matrix-M ™ to enhance immune responses with COVID-19 vaccine candidates.
Status: Novavex agreed to use the Emergent Biosolution Molecule Market Contract (CDMO) development and manufacturing services to support the clinical development of the COVID-19 vaccine candidate.
Emergent said he agreed to produce the candidate vaccine on March 10 and began work anticipating that the candidate vaccine would be used in Phase I studies within the next four months.
On February 26, Novavax cited progress in its development, stating that it is currently evaluating several candidates for nanoparticle vaccines in animal models before identifying an optimal candidate for human testing.
Type: broad-spectrum antiviral activity in laboratory tests against SARS-CoV-2 and MERS-CoV, as well as specific dual-target antiviral activity against Ebola-like filoviruses. OYA1 received IND approval in 1960 as a candidate to treat cancer, but it lacked efficacy.
Status: On March 11, Oyagen announced unpublished research results in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) at the Center for Integrated Research in Fort Deitrick, MD.
According to infectious studies of the cell culture suggested strong dose-dependent antiviral activity of its key compound OYA1 against live SARS-CoV-2, the company said it would conduct further studies.
“The company anticipates that inhibiting SARS-CoV-2 using OYA1 will serve as an interim treatment until the appropriate vaccine is developed,” said Ogen.
Treatment: antiviral compound
Type: not specified
Status: Pfizer said on March 2 that it had recently completed a preliminary evaluation of antiviral compounds that were in development and that it inhibited the replication of the coronavirus, similar to the production of COVID-19 in cultured cells.
Pfizer said it was engaging with third parties to test these compounds on a fast schedule and that the results were expected to return in late March.
“The toxicology study will need to be completed before any clinical development, but if it is successful, Pfizer is expected to be in the clinic by the end of 2020,” the company said.
48. No sound
Treatment: Arbidol (Euphenovir)
Type: membrane fusion inhibitors developed as a treatment for influenza
Status: In standard clinical trials, arbidol is evaluated as monotherapy and in combination with Caletra from ABVE (see above), ASC09 from Escalates Pharma (see above), lopinavir, ranovir, caramicine and bromhexine hydrochloride (by invitation). Nomination). Six trials, including arbidol, were included on clinictrial.go.
Monotherapy tests (NCT04260594) are held at Ruijin Hospital in China, while the Famous Jiangsu Medical Technology Company COVID-19 (NCT04306497) will include Arbidol in western medicine options compared to traditional Chinese medicine and will examine various Chinese hospitals. You are undergoing other combination therapy (NCT04252885, NCT04273763, NCT04261907, NCT04286503).
49. Q Biomed and Manin Research
Type: The potential first-line drug for intraocular eye pressure in primary open-angle glaucoma as a complementary treatment for vascular leakage and endothelial dysfunction observed in COVID-19 and other infectious diseases has been based on a central stage of research. It is Partner manin research, which is designed to target activation of the angiopatin-Th2 signaling pathway.
Status: In its annual Form 10-K report filed on February 28, Q Biomed stated that the MAN-01 methodology can cause damage to the vasculature in diseases including “infectious diseases, such as influenza and current coronavirus outbreaks It is “.
Q Biomed and Mannin Research announced their collaboration on February 4. In September 2019, the German state of Saxony awarded Manin a grant of approximately $ 7.7 million to advance his new therapies, including drugs and biologics that reduce endothelial dysfunction and loss of endothelial barrier integrity.
Mannin recently submitted a request for funding for the NIH Small Business Technology Transfer Grant to examine specific applications of Mannin’s therapeutic platform.
50. Redhill Biopharma
Treatment: Opaganib (Yeliva®, ABC294640) and RHB-107.. Type: Opagnib is a first-class, orally administered sphingosine kinase-2 (SK2), a selective inhibitor with anti-cancer and anti-inflammatory activities, targeting multiple oncological, inflammatory, and gastrointestinal signals.
RHB-107 is a first-class orally administered inhibitor with the S1 family of the trypsin-like serine family with potential for use in many oncological, gastrointestinal, and inflammatory indications.
Status: Redhill said on March 11 that it was personally searching for Opnigib and RHB-107 and based on preclinical data and literature, in combination with hydroxychloroquine and other compounds, as a COVID-19 treatment. That reflects possible antiviral activity.
Opagnib was originally developed by Apoji.
Biotechnology, which received United States federal and state development grants and contracts. RedHill has licensed RHB-107 from Heidelberg Pharma (formerly Wilkes) worldwide, except China, Taiwan, Macao and Hong Kong.
51. Regeneron Pharmaceuticals
Treatment: antibody cocktail therapy; REGN3048 and REGN 3051… Type: A combination of neutralizing monoclonal antibodies that make Regeneron’s monoclonal antibody discovery platform part of the company’s VelociSuite ™ technologies called VelocImmune®.
Status: On March 17, Regeneron announced progress in the development of a cocktail antibody therapy against COVID-19, claiming that it genetically isolated hundreds of completely human virus-neutralizing antibodies from its veloimmune mice.
Modified human immune system: as antibodies to humans recovered from COVID-19. Of these antibody candidates, Regeneron said, he would choose the two main antibodies to treat the ‘cocktail’ “based on the capacity and binding capacity of the SARS-CoV-2 tip protein.
As well as other desirable properties” . Regeneron said he is working to produce hundreds of thousands of prophylactic doses per month by the end of summer, and in small quantities for early clinical trials in early summer.
Regeneron has also stated that he is developing a combination of REGN3048 and REGN3051 as a CONID-19 treatment. The combination completed a Phase I test at MERS-CoV (NCT03301090) last year. On February 4, the Advanced Biomedical Research and Development.
Authority (BARDA) stated that a partnership agreement with Regeneron was extended to develop several earlier “monoclonal antibodies”. It can be used for new treatments, either individually or in combination. “
52. Regeneron Pharmaceuticals and Sanofi
Treatment: Kevara® (Sarilumab)
Type: Interleukin-6 receptor antagonist (IL-6) was approved by the FDA in 2017 to treat adults with very active rheumatism who have an inadequate response to one or more of the anti-inflammatory drugs OR had intolerance.
Status: On March 16, Regeneron Pharmaceuticals and Sanofi stated that they did a phase II / phase III Kevzara treatment in the USA. USA In patients with severe COVID-19 infection.
He started clinical trials and will begin recruiting patients immediately. 400 adults hospitalized with serious complications from COVID-19 will be evaluated for implementation at medical centers in New York.
The primary end point for stage II is feverlessness and the secondary end point reduces the need for supplemental oxygen. The third phase will assess improvements in long-term outcomes.
Including preventing death and reducing the need for mechanical ventilation, supplemental oxygen, and / or hospitalization. Regeneron, USA USA He will direct clinical studies, while Sanofi will do it abroad.
53. Roshe (Genentech)
Treatment: Actemra (tocilizumab)
Type: Interleukin-6 receptor antagonist (IL-6) was approved by the FDA in 2010, with signs of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
Status: Genentech said March 13 was in “active discussion” with the FDA and other government agencies and institutions to begin clinical trials for ACTEM in critically ill patients with COVID-19, and said: “There are as many details as we can provide in this moment “.
The Chinese National Health Commission included Actemra in its seventh updated diagnosis and treatment plan for COVID-19 earlier this month to treat patients with high levels of IL-6 and severe lung damage.
Three trials evaluating Actemra have been registered in the China Clinical Trials Register: one out of 198 patients (ChiCTR2000029765), one out of 60 patients with Jinyu Bio-Technology Company, who is taking drugs like CMAB6 (ChiCTR2000030196) Markets, and assesses a combination of. Actemra, intravenous immunoglobulin (IVIG) and continuous renal replacement therapy (CRRT) (ChiCTR2000030442).
Type: Vaccine based on Sanofi’s recombinant DNA platform, designed to make an exact genetic match with the proteins found on the surface of the virus. Sanofi claimed that the DNA sequence encoding the antigen would be conjugated to the DNA of the baculovirus expression platform and would be used for the rapid production of large amounts of coronovirus antigens to stimulate the immune system to protect against viruses. Will be prepared.
Status: John Reid, MD, PhD, Sanofi’s Global Head of Research and Development, reestablished on March 16 that Sanofi Pasteur was quickly a COVID-19 based on previous development work for the SARS vaccine through a collaboration. The global business unit is planning to develop the vaccine.
With the Advanced Biomedical Research and Development Authority (BARDA).
In non-clinical studies, the candidate for the SARS vaccine was immunogenic and provided partial protection as evaluated in animal challenge models, Sanofi said, February 18. Previous Science of Proteins work, which was acquired by Sanofi in 2017, “provides an important start in accelerating a COVID -19 vaccine,” Sanofi said.
55. Tijiana Life Sciences and Novimune
Type: Licensed by Novimune in January 2017, targeting the receptor for the fully human monoclonal antibody IL-6. TSLLS501, which will be administered using a proprietary formulation technique, is designed to bind to both membrane-bound and soluble forms of IL. -6R, and rapidly increasing levels of IL-6 in the blood.
Status: On March 11, Tiziana said she would accelerate development of the TZLS-501 with Novimmune, with a global license granted in 2017. Tiziana believes that excessive production of IL-6 is a major driver of chronic inflammation, believed to be It is associated with severe lung damage observed with COVID-19 infection and acute respiratory disease.
The Chinese National Health Commission recommends the use of anti-IL6-R monoclonal antibodies to treat inflammation and elevated levels of cytokines (cytokine storm) in patients with COVID-19.
56. Tonics Pharmaceuticals Holding
Type: Modified live varicella virus vaccine for percutaneous administration
Status: Tonics stated that on February 26 it partnered with Southern Research to develop COVID-19 TKX-1800 as a vaccine treatment. TNX-1800 is being developed as a possible smallpox vaccine for the US Strategic National Repository. USA And as a vaccine prevention suit.
57. Waxart and emerging biosolutions
Treatment: the vaccine is based on the patented VAAST ™ platform.. Type: tablet-based recombinant oral vaccine
Status: On March 9, Waxart agreed to use Emergent Biosolutions ‘Molecule-to-Market’ (CDMO) contract development and manufacturing services to develop and manufacture Waxart’s experimental oral vaccine for COVID-19.
Development services will begin immediately, and after Waxart’s election, Amergent is expected to produce the cGMP vaccine in bulk, allowing Waxart to begin a Phase I clinical trial in the late 2020s. Emergent said who will provide development services outside of their Gaithersburg, MD location.
And manufacturing pharmaceuticals at its Bayview facility in Baltimore, designated the Center for Innovation in Advanced Development and Manufacturing (ICSID) by the Department of Health and Human Services.
Vaxart revealed in January that it plans to generate vaccine candidates based on the published SARS-nCoV-2 genome, and evaluate them in preclinical models based on their ability to elicit both mucosal and systemic immune responses.
58. See biotechnology and biogen
Treatment: human monoclonal antibody
Type: The monoclonal antibody is designed to bind to SARS-CoV-2, and has been identified through the Vir antibody platform. Veer Engineer fully detects human antibodies in order to enhance their therapeutic potential.
Status: Veer stated that on March 12, it signed a letter of intent with Biogen, pursuant to which Biogen agreed to carry out development, process development and clinical manufacturing activities for the cell, while in formal clinic Negotiating agreements development and manufacturing.
Weir said he is conducting an investigation to determine if his antibodies, or additional antibodies that he can identify, can effectively treat and / or protect against SARS-CoV-2.
Four days later, Biogen announced that the Biogen Foundation has paid $ 10 million to support global response efforts and communities around the world that have been affected by COVID-19.
59. Veer Biotechnology and NIAID
Treatment: human monoclonal antibody
Type: The monoclonal antibody is designed to bind to SARS-CoV-2, and has been identified through the Vir antibody platform. Veer Engineer fully detects human antibodies in order to enhance their therapeutic potential.
Status: VR said that on March 11, the NIH will partner with the National Institute of Allergy and Infectious Diseases (NIAID), the Vaccine Research Center, to combine SARS-COV-2 and antibodies against other coronavirus, including SARS and MERS. Identify and optimize.
In addition to the antibodies that can be effective in additional types of coronaviruses. The partners will exchange antibodies and other materials in combination and individually for testing and, by mutual agreement, they will conduct in vivo studies in animals to analyze the immune response.
60. Veer Biotechnology and Wuxi Biologics
Treatment: Human monoclonal antibodies not yet known
Type: Human monoclonal antibodies have been shown to bind SARS-CoV-2, isolated from individuals with a severe acute respiratory syndrome (SARS) infection.
Status: On February 25, Vir Biotechnology announced a development and manufacturing collaboration with Wuxi Biolics to search for and produce human monoclonal antibodies as a potential treatment for COVID-19.
The antibodies were discovered through the company’s antibody platform, which has been used to identify and develop antibodies against pathogens, including Ebola (mAb114, currently used in the Democratic Republic of the Congo), Hepatitis B. Viruses, influenza A, malaria and others.
If the antibodies obtain regulatory approval, Wuxi Biologics has marketing rights in all other world markets in Greater China and Vir.